After the emotional scenes nearly two months ago at the end of COP26, has a bit of distance provided any more perspective on the outcomes? Read more …

President Biden’s Build Back Better agenda has reignited the debate about drug pricing. Arguments generally fall into two camps. On the one hand is concern about the increasing burden of health care costs. On the other hand, are arguments that drug prices are needed to support innovation and recoup the high cost of failures.

For impact investors, this is an important issue. Read more …

Climate change has become such an all-encompassing threat, that most other environmental concerns have been left in its shadow. The decline in biodiversity is one such issue that rarely receives the attention that it deserves. Read more …